FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population ...

The FDA has approved an expanded indication for setmelanotide to treat children and adults with acquired hypothalamic obesity, Rhythm Pharmaceuticals announced. Setmelanotide (Imcivree, Rhythm ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and ...

PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals received Food and Drug Administration approval for an expanded indication for setmelanotide, its treatment for acquired hypothalamic obesity. Acquired hypothalamic obesity is a ...

The U.S. Food and Drug Administration (FDA) on Thursday approved an expanded indication for Rhythm Pharmaceuticals Inc.’s RYTM Imcivree (setmelanotide) to treat acquired hypothalamic obesity (HO). The ...

Metabolic syndrome (MetS) is a multifaceted disorder that impacts approximately 20–25% of the global population. This syndrome encompasses a range of conditions, including obesity, type 2 diabetes ...

Hypothalamic obesity is a complex condition that doesn’t always respond to traditional weight loss methods. Medications, hormonal therapy, and surgery may be necessary to see results. Hypothalamic ...

Please provide your email address to receive an email when new articles are posted on . Setmelanotide was linked to reduction in BMI at 52 weeks compared with placebo for patients with acquired ...